Business Context and Reporting Period
This Form 8-K, dated November 16, 2022, is filed by Chavant Capital Acquisition Corp. (Chavant) to announce a business combination agreement with Mobix Labs, Inc. (Mobix Labs). Under the terms of the agreement, a newly formed subsidiary of Chavant will merge with Mobix Labs, with Mobix Labs surviving as a wholly-owned subsidiary. The combined entity will be named Mobix Labs, Inc. and is expected to list its common stock and warrants on the Nasdaq Stock Market.
Key Financial Metrics
This filing is a current report regarding a proposed transaction and does not contain audited financial statements, revenue, profit, cash flow, or margin data for either Chavant or Mobix Labs. Specific financial metrics such as debt levels, liquidity positions, or valuation figures are not provided in the text of this 8-K; investors are directed to the forthcoming Form S-4 registration statement and proxy statement/prospectus for detailed financial information.
Material Changes
The primary material change disclosed is the execution of a definitive business combination agreement on November 15, 2022. This represents a significant corporate development for Chavant, transitioning it from a special purpose acquisition company (SPAC) to a combined operating company with Mobix Labs. No historical financial comparisons are included in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the transaction and the expectation that the combined company will operate under the Mobix Labs name. The filing includes extensive forward-looking statements regarding the anticipated benefits of the transaction, the sufficiency of net proceeds to fund operations, and growth plans. However, the document explicitly states that neither Chavant nor Mobix Labs gives any assurance that expected results will be achieved.
Key risks and contingencies identified include:
- Failure to complete the transaction in a timely manner or at all.
- Failure to satisfy conditions for consummation, including shareholder approval and regulatory approvals.
- Failure to meet the minimum cash amount following redemptions by Chavant's public shareholders.
- Inability to complete the PIPE investment or secure funding under an equity line of credit.
- Disruption of Mobix Labs' business relationships and employee retention.
- Volatility in Chavant's securities price due to market conditions and the transaction's pendency.
- Challenges in developing and marketing Mobix Labs' products or achieving profitability.
Investor Verification Checklist
- Verify the final terms of the business combination in the upcoming Form S-4 and proxy statement/prospectus.
- Confirm the status of the PIPE investment and the equity line of credit, as their completion is a risk factor.
- Monitor the redemption rate of Chavant's public shareholders to ensure the minimum cash condition is met.
- Review the detailed risk factors in Chavant's 2021 Form 10-K and subsequent 10-Q filings referenced in this document.
- Check for any updates regarding the timeline for the shareholder vote and regulatory approvals.